CSIMarket
 
Ocular Therapeutix Inc   (OCUL)
Other Ticker:  
 
 
Price: $9.4400 $-0.02 -0.211%
Day's High: $9.63 Week Perf: 1.61 %
Day's Low: $ 8.96 30 Day Perf: 37.61 %
Volume (M): 1,760 52 Wk High: $ 11.31
Volume (M$): $ 16,618 52 Wk Avg: $4.86
Open: $9.46 52 Wk Low: $2.00



 Market Capitalization (Millions $) 747
 Shares Outstanding (Millions) 79
 Employees -
 Revenues (TTM) (Millions $) 58
 Net Income (TTM) (Millions $) -81
 Cash Flow (TTM) (Millions $) 94
 Capital Exp. (TTM) (Millions $) 6

Ocular Therapeutix Inc
Ocular Therapeutix Inc is a pharmaceutical company that specializes in the development and commercialization of innovative therapies for diseases and conditions affecting the eye. They focus on creating sustained-release drug delivery systems to improve the effectiveness and convenience of eye treatments. Their products aim to address various ocular disorders such as glaucoma, dry eye disease, and allergic conjunctivitis. Ocular Therapeutix aims to provide patients with long-lasting and efficient treatments that reduce the need for frequent medication administration.


   Company Address: 15 Crosby Drive Bedford 1730 MA
   Company Phone Number: 357-4000   Stock Exchange / Ticker: NASDAQ OCUL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Ocular Therapeutix Inc

2. Struggling Ocular Therapeutix Inc Reports Higher Losses Despite Revenue Growth

Ocular Therapeutix Inc (OCUL) seems to be facing some significant challenges based on its recent financial performance. In the fiscal period from October to December 31, 2023, the company reported a loss per share of $-0.27, compared to $-0.19 from the previous year. This represents a surge in losses from the prior reporting season where the loss per share was $-0.25.
Furthermore, despite a growth in revenue by 5.158% to $14.80 million from $14.08 million in the same reporting season a year prior, there was a sequential decrease in revenue of -1.85% from $15.08 million. This indicates a potential decline in demand or challenges in maintaining consistent revenue growth.
The net loss for the October to December 31, 2023 fiscal span was $-29.220 million, significantly larger than the $-15.542 million loss from a year ago. This substantial increase in losses raises concerns about the company's financial stability and ability to generate profits.

Stock Market Announcement

Ocular Therapeutix Grants Inducement Awards to Newly Appointed Executives, Symbolic of Continued Company Growth and Commitment to Advancing Ophthalmic Therapies

Published Thu, Feb 22 2024 12:32 PM UTC


Ocular Therapeutix has been making significant strides in the ophthalmic field, and the addition of Dr. Dugel and Dr. Nayak to their executive team further strengthens the company's expertise and strategic vision. This move reflects Ocular's commitment to attracting top talent in the industry in order to advance the development and commercialization of groundbreaking oc...

Dividend

Ocular Therapeutix Raises $325 Million in Private Placement to Advance Vision-Enhancing Therapies

Published Thu, Feb 22 2024 12:31 PM UTC



Ocular Therapeutix, Inc. has made headlines yet again with its latest announcement of securing $325 million in a private placement deal. The Massachusetts-based biopharmaceutical company has successfully entered into a securities purchase agreement with several institutional accredited investors, aiming to accelerate the development and commercialization of innovat...

Clinical Study

Shaping the Future of AMD Treatment: Ocular Therapeutix's AXPAXLI Intravitreal Implant Holds Promise in Pivotal Phase 3 SOL-1 Study

Published Tue, Feb 13 2024 12:38 PM UTC

Ocular Therapeutix's AXPAXLI Shows Promise for Treating Wet Age-related Macular Degeneration: A Comprehensive Review of the Phase 3 SOL-1 StudyOcular Therapeutix recently announced the initiation of the Phase 3 SOL-1 study, which aims to evaluate the efficacy and safety of their investigational drug, AXPAXLI, in treating wet age-related macular degeneration (AMD). This key m...

Clinical Study

Enhancing Patient Eligibility and Improving Outcomes: FDA Amends Special Protocol Assessment for AXPAXLI in Wet AMD Clinical Trial

Published Thu, Jan 25 2024 1:00 PM UTC

The treatment landscape for wet age-related macular degeneration (Wet AMD) is constantly evolving, with researchers and medical professionals striving to develop more effective and patient-friendly therapeutic options. Among these advancements, Ocular Therapeutix has recently announced a significant breakthrough in their ongoing clinical trial for AXPAXLI, a promising treatm...






 

Ocular Therapeutix Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Ocular Therapeutix Inc does not provide revenue guidance.

Earnings Outlook
Ocular Therapeutix Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com